Structures by: Dabros M.
Total: 6
C21H17BrF3N3O3
C21H17BrF3N3O3
Journal of medicinal chemistry (2018)
a=10.3211(4)Å b=19.6960(7)Å c=21.4630(9)Å
α=90.00° β=90.00° γ=90.00°
BMS-927711-0.5H2SO4 H1.5-1 sesquihydrate CGRP
C28H29F2N6O31,0.5(O4S12),1.5(H2O1)
Acta Crystallographica Section B (2014) 70, 3 555-567
a=10.9169(9)Å b=33.039(3)Å c=7.9038(6)Å
α=90.00° β=90.00° γ=90.00°
3-Ethynylpyridine
C7H5N
Crystal Growth & Design (2007) 7, 4 598
a=3.8294(12)Å b=6.0334(17)Å c=12.139(5)Å
α=90.00° β=96.23(3)° γ=90.00°
5-Ethynylpyrimidine
C6H4N2
Crystal Growth & Design (2007) 7, 4 598
a=3.8710(6)Å b=13.890(2)Å c=10.2043(15)Å
α=90.00° β=94.547(4)° γ=90.00°
4-Ethynylpyridine
C7H5N
Crystal Growth & Design (2007) 7, 4 598
a=7.371(6)Å b=8.701(4)Å c=9.303(5)Å
α=90.00° β=109.05(4)° γ=90.00°
2-Ethynylpyridine
C7H5N
Crystal Growth & Design (2007) 7, 4 598
a=8.329(3)Å b=17.494(8)Å c=8.327(3)Å
α=90.00° β=90.00° γ=90.00°